The protein Kinase A (PKA) pathway was found to selectively regulate the function of oncogenic but not non-oncogenic E6 proteins. High risk E6 proteins are phosphorylated at their Dlg/PDZ binding motif at the C-terminus by a PKA like activity. This PKA and PDZ binding module is found only for human PV, is strictly conserved in all the transforming HPVs and is absent in all the low risk HPV types. We present evidence of a conditional regulation of E6 induced degradation of Dlg. HPV18E6 positive but not HPV negative keratinocytes exhibit increased Dlg steady state levels under conditions of high PKA activity, with a concomitant increase in the presence of Dlg at tight junctions. In vitro binding experiments show that E6 phosphorylation by PKA reduces its binding to Dlg and molecular modelling can explain this observation in a structural context. E6 dependent degradation of Dlg in cells with high PKA levels is inhibited and this is dependent on phosphorylation of the PDZ binding site in E6. In contrast, the degradation of p53 induced by E6 is not aected by PKA. We propose a dierential regulation of E6 for the ubiquitin mediated degradation of speci®c E6 target proteins. Oncogene (2000) 19, 5884 ± 5891.
Introduction
Human papillomaviruses (HPV) are considered to be the causative agent of over 90% of all genital cancers characterised (zur Hausen, 1991 (zur Hausen, , 1996 . Only a small number of HPV isolates (designated high risk or oncogenic types), of the more than 100 dierent HPV types known (de Villiers et al., 1997) are associated with genital cancer. High risk HPVs encode two oncogenes, E6 and E7, which are thought to interfere with crucial cellular factors that are important for the control of cell proliferation and dierentiation. The expression of these oncogenes is essential but not sucient for the development of malignant growth. The long latency periods between HPV infection and development of HPV associated tumours suggests the involvement of additional cellular factors for the manifestation of HPV induced genital cancer (zur Hausen, 1991 (zur Hausen, , 1996 .
High risk HPV-E6 proteins target the tumour suppressor p53 for ubiquitin mediated degradation and thereby serve as processivity factors for the ubiquitin ligase E6-AP (Crook et al., 1991; Schener et al., 1995; Werness et al., 1990) . In this respect, E6 neutralises a cellular surveillance pathway and, as an outcome, can have anti-apoptotic function. More recently additional high risk E6 speci®c cellular targets, the nuclear proliferation proteins c-Myc (GrossMesilaty et al., 1998), Mcm7 (KuÈ hne and and the apoptosis inducer Bak (Thomas and were found to be processed for ubiquitin mediated degradation in an E6/E6-AP dependent manner. Despite these well characterized activities of E6 with respect to cell growth control, little is known about the molecular mechanisms for a presumptive involvement in perturbations of terminal cellular dierentiation and cell adhesion which are essential prerequisites for malignant transformation. Recent experiments in transgenic mice show that the E6 oncoprotein alone is sucient to induce malignant skin tumours at one year of age (Song et al., 1999) . In addition E6 has also been shown to perturb cellular dierentiation independently of its association with p53 (Pan and Griep, 1995; Song et al., 1999) . The recent discovery that E6 binds to the vertebrate orthologues of the Drosophila M. discs large-1 gene-product Dlg/ Sap97, a candidate tumour suppressor protein (Kiyono et al., 1997; Lee et al., 1997) is the ®rst example of HPV interference with a component of the cell adhesion signalling apparatus during carcinogenesis. The Dlg protein contains three PDZ domains and these domains interact with the C-terminal PDZ-binding motif of the E6 oncoproteins. This region in E6 was previously shown not to be involved in p53 binding (Crook et al., 1991; Foster et al., 1994; Pim et al., 1994) . Intriguingly human Dlg binds directly via the PDZ domains to the C-terminus of the adenomatous polyposis coli gene product (APC), a somatically mutated gene in the majority of sporadic colorectal tumours (Kinzler and Vogelstein, 1996) .
Extra-cellular signals, such as hormones and neurotransmitters, can function by increasing the intracellular levels of the second messenger cyclic adenosine 3',5'-monophosphate (cAMP) and activate guanosine triphosphate (GTP) binding protein-mediated cAMPdependent signalling cascades. An increase in the cellular levels of cAMP mediates the phosphorylation activity of its main downstream target, the serine/ threonine kinase PKA and in this way links extracellular signals to a variety of PKA regulated cellular functions (Krebs and Beavo, 1979; Taylor et al., 1990) .
Depending on the type and status of a cell, the outcome of an increase in cAMP can be as diverse as activation or inhibition of cell proliferation and cell cycle progression (Boynton and White®eld, 1983; Fernandez et al., 1995; Kato et al., 1994) .
We showed recently (Gardiol et al., 1999) that E6 also targets Dlg for ubiquitin mediated degradation. Unlike E6/E6-AP targeted degradation, Dlg-PDZ domains (Kiyono et al., 1997; Lee et al., 1997) are targeted by high risk E6 proteins using a four amino acid binding motif at the very C-terminus, which is essential and sucient for their interaction. In this communication, we show that this viral Dlg/PDZ binding motif is phosphorylated in a PKA dependent pathway. This post-translational modi®cation of E6 causes inhibition of the E6 mediated turnover of the tumour suppressor protein Dlg, whereas the E6 dependent degradation of p53 is unaected. Thus, PKA phosphorylation of E6 represents a means of dierentially regulating the timing of E6 dependent ubiquitin mediated degradation of Dlg. We suggest that this protein kinase A dependent regulation of the DNA tumour-virus oncogene E6 links the malignant progression of HPV immortalized cells to the levels of cAMP.
Results

HPV 18E6 is a protein kinase A substrate in vitro
We were interested in cellular factors that selectively regulate the function of oncogenic HPV-E6 proteins. We observed that NIH3T3 cell extracts exhibit a kinase activity that speci®cally phosphorylates a glutathione-S-transferase-18E6 fusion protein (GST-18E6) ( Figure  1A ). This activity was strongly reduced in the presence of a protein kinase A (PKA) inhibitor peptide (PK-i) at 10 mM, a concentration previously shown to be selective for PKA (Glass et al., 1989) (Figure 1A ). In contrast, treatment of the cells prior to extract preparation with wortmanin, rapamycin or high Ca 2+ did not change this kinase activity (data not shown). Further in vitro assays de®ned GST-16E6 but not the low risk type GST-11E6, as a substrate for PKA, suggesting that this phosphorylation might be speci®c to high risk HPV E6 proteins ( Figure 1B) . The HPV-18E6 protein contains one region that matches the PKA consensus RXX(S/T), Thr 156 (RRET). A GST-18E6 protein with a Thr 156 to Val substitution mutation was no longer a PKA substrate ( Figure 1C ), indicating that Thr 156 is the phospho-acceptor site for the PKA like activity observed from these extracts in vitro.
More than 85% of HPV associated cancers contain HPV 16 or HPV 18. As suggested from phosphorylation experiments of E6 proteins from these types using GST-16E6 and GST-18E6 as substrates ( Figure 1 ) the C terminal PKA phosphorylation was speci®c and very ecient. In fact we determined a very low Michaelis constant (K m ) of 2.5 mM for GST 18E6 ( Figure 1D ; a). We also tested kinases that exhibit partially overlapping substrate-speci®city with the PKA phosphorylation-site consensus (RXXS/T) (Leighton et al., 1995) against GST-18E6. Puri®ed recombinant p70 S6-kinase as well as immunoprecipitates of PKB (AKT1) or p90 rsk (MAPKAP) kinase, did not speci®cally phosphorylate the HPV-18E6 peptides, giving K m values in the mM range ( Figure 1D ; a). This demonstrates that a GST-18E6 substrate exhibits a high degree of selectivity for PKA over these other kinases.
In addition we used synthetic peptides to determine the potential of other, minor represented high-risk HPV-E6 members to serve as PKA substrates ( Figure  1D ; b). All the E6 C-terminal peptides tested show comparable substrate constants towards PKA. These are all in the low mM range, similar to the K m determined for full-length GST-18E6 protein and of note, are among the lowest K m values described for PKA peptide substrates in the literature (Kemp et al., 1975) . A mutant peptide that contains a Leu substituted for the essential Arg 152 in the PKA substrate recognition motif in HPV-18E6, did not show speci®c constants and thus is not a substrate for PKA (Figure 1D ; b; the importance of this mutant will be discussed later in the text). This demonstrates the evolutionary conservation of the high-risk E6 proteins as being substrates for PKA in vitro.
HPV-18E6 is a phosphoprotein in vivo
To determine whether HPV-18E6 is phosphorylated in vivo, the epithelial cell-line HEK293 was transiently (Figure 2A ; b) (see later in the text) were added for the last hour of the labelling period. Cell extracts were prepared and 18E6 protein was immunoprecipitated with HA speci®c antibodies. Figure 2A shows that HPV-18E6 is a phospho-protein in vivo, and the 18E6 speci®c input of [ 32 P] is increased in the presence of activators of the PKA pathway (for Figure 2A ; measured increase (b to c) was 2.4 times). Protein expression under dierent PKA levels was comparable as estimated from immuno-blots of the labelled HA-18E6 proteins with HA antibodies ( Figure 2B ; lanes b and c). The fact that the speci®c HPV-18E6 phosphorylation is increased in response to high PKA activity in vivo correlates with the in vitro phosphorylation data for HPV-18E6 and taken together, suggests that HPV 18E6 is a substrate for PKA or a PKA like activity in a cellular environment. Taking together the kinetic measurements, the low kinase activity of whole cell extracts towards GST-18E6 in the presence of a PKA inhibitor peptide, and the speci®c phosphorylation of HPV 18E6 in HEK293 cells, these results suggest that protein kinase A is a good candidate for being an`E6 C-terminal kinase' both in vitro and in vivo.
HPV-18E6/Dlg interaction is modulated by Thr 156 phosphorylation in vitro
Recently a high risk speci®c HPV-E6/Dlg interaction was shown. Substrate selection and binding sites were mapped to the C-terminal four amino acids of the E6 proteins and the three PDZ-domains in Dlg (Kiyono et al., 1997; Lee et al., 1997) . The putative phosphorylation of E6 in its PDZ binding motif implied a possible regulation for the E6/Dlg interaction. Moreover, a precedent conditional regulation by PKA has been reported for the interaction of the inward recti®er K + channel Kir 2.3 protein with the PDZ domains of psd95 (Cohen et al., 1996) . To test this possibility we used recombinant 18E6 tagged with six histidines (His18E6) and analysed its binding to a puri®ed GST-Dlg protein in vitro ( Figure 3A ; lane 3). After intensive washing, bound His18E6 protein was eluted and analysed in Western blots using an anti HPV-18E6 antibody. We compared this interaction to a reaction with the same amount of His18E6 protein that was previously phosphorylated with PKA ( Figure 3A ; lane 4). Estimated phosphorylation eciency was 80% (+10%) and the GST-Dlg protein was used in a ®ve-fold molar excess over His18E6. Additional controlprecipitations with GST alone were included ( Figure  3A ; lanes 1, 2). The results show speci®c retention of the non-phosphorylated His18E6 proteins, whereas binding to phosphorylated His18E6 proteins was strongly reduced. In addition C-terminal E6 peptides were able to compete for the His-18E6/GST-Dlg in vitro interaction ( Figure 3A ; lane 5), whereas E6 peptides that contained a corresponding phosphoThr 156 were not ( Figure 3A ; lane 6).
We then undertook molecular modelling of the 18E6 C-terminus. We calculated the structure of the HPV-18E6 C-terminal amino acids RETQV and RE(p)TQV and determined that the non-phosphorylated form was super-imposable with the experimentally determined crystal structure of the psd95 substrate (Doyle et al., 1996) (Figure 3B ; upper panel). In the phosphorylated form the distances between the PDZ domain contacting carboxyl group of the C-terminal Val and the phospho-Thr were too far apart for speci®c recognition (10.35 A Ê versus 13.35 A Ê for the phospho-Thr) ( Figure 3B ; lower panel). In addition, the introduction of a phosphate positions the essential Glu 155 away from the calculated, nonphosphorylated peptide structure. This is of importance, as this position was determined as crucial for PDZ type speci®city selection. Moreover, molecular dynamic studies suggest that the previously determined PDZ contacting atoms (Doyle et al., 1996) from Val 158 and Thr 156 are¯exible, which should allow substrate selection. Interestingly introduction of a phospho-Thr 156 stabilises the predicted C-terminal structure in its unbound state (total energies are 788.509 eV for the unphosphorylated, versus 7249.982 eV for the phosphorylated structure; Amenitsch H and KuÈ hne C unpublished results).
Taken together these studies show that the E6/Dlg interaction is inhibited by Thr 156 phosphorylation on E6 and the minimal energy calculations place these results into a rational, structural context and demonstrate that Dlg substrate selection is impaired for the PKA phosphorylated form of E6.
Dlg is stabilized in response to increased PKA activity in HeLa cells
We next analysed the endogenous hDlg steady state levels under conditions of low and high PKA activity in a HPV 18 positive HeLa cells and HPV negative HaCaT cells. These cells were plated at low density and extracts were analysed for Dlg and for comparison for p53, under conditions of low or high PKA activity ( Figure 4A ; left panels). In parallel, to test if the cells P-orthophosphate and whole cell extracts were analysed for 18E6 protein by immunoprecipitations with HA speci®c monoclonal antibodies. Precipitates were run on a SDS ± PAGE. Dried gels were analysed by the aid of a phosphoimager. (B) Expression of the E6 proteins under low and high PKA activity was analysed in parallel in Western blots from the same extracts as used in A. Loading represents 10% of the input used for the immunoprecipitation in A. Detection was with HA speci®c antibodies. For panels A and B the lanes are as follows: pCMV (a); pCMV-HA18E6 (b,c). The PKA activators forskolin and IBMX was added 1 h prior to cell-harvest (c). The activator concentrations were as in Figure 5 and PKA activities were comparable to values obtained for the experiment shown in Figure 5 . Arrows mark the position of HA-18E6; (*) low molecular weight HA and E6 speci®c band and growth conditions used were responsive to PKA activators, PKA induction was determined ( Figure 4A ; right panel). In HeLa cells, endogenous Dlg and p53 levels are very low, and Dlg and p53 proteins are stabilized in the presence of proteasome inhibitors (F Mantovani and L Banks, submitted for publication; Maki et al., 1996) . However, the induction of PKA activity results in an increase in the level of Dlg protein, whereas p53 does not change signi®cantly ( Figure 4A ; left panels), suggesting a conditional stabilization of Dlg, but not of p53, upstream of the proteasome (see later in the text). In contrast, in HaCaT cells where Dlg is readily detectable, the levels did not change in response to PKA induction ( Figure  4A ; left panels).
Dlg localises to tight junctions and was shown to be required for the formation and maintenance of these junctions in epithelial cell dierentiation, which is thought to establish apico-basal polarity (Balda and Matter, 1998; Ponting et al., 1997) . We next analysed the cellular localisation of Dlg in HeLa and HaCaT cells under low and high PKA conditions by confocal microscopy. HaCaT cells show strong Dlg staining in both high and low PKA activity and Dlg can be detected at cell junctions ( Figure 4B ). In contrast using the same microscopic settings for HeLa cells in low PKA activity, Dlg was only weakly detectable. However upon PKA induction, Dlg could be detected at junction like structures ( Figure 4B ). Taken together these results demonstrate that Dlg levels can be 
E6 phosphorylation by PKA inhibits E6 mediated degradation of the Dlg protein in vivo
We have previously shown that E6 speci®cally targets Dlg for ubiquitin mediated degradation (Gardiol et al., 1999) . The experiments presented above suggest that this degradation might be conditionally regulated by the PKA pathway. Therefore we designed an experiment to ask if the 18E6 mediated degradation of Dlg is regulated by E6 phosphorylation through the PKA pathway in vivo. To do this, 18E6 dependent in vivo Dlg degradation assays were performed, under conditions of high or low PKA activity. High PKA was obtained either by transfecting a plasmid expressing the cDNA for the catalytic subunit of PKA (Uhler and McKnight, 1987) or by raising the intra-cellular cyclic-AMP levels with a combination of the adenylatecyclase activator forskolin and the phosphodiesterase inhibitor IBMX ( Figure 5C ) (Wu et al., 1993) . In agreement with previous observations, cotransfection experiments of plasmids expressing HA-tagged Dlg protein and plasmids expressing HPV-18E6 showed destabilisation of HA-Dlg ( Figure 5A, lane b) . Strikingly, however, at high PKA levels the HA-Dlg protein was stabilised, as can be seen from contransfection experiments of HPV-18E6 with plasmids expressing the catalytic subunit of PKA ( Figure 5A , lane c) or from experiments where HPV-18E6 transfected cells were incubated for two hours in the presence of forskolin and IBMX ( Figure 5A, lane d) . Further, a non-phosphorylatable, but Dlg-binding, mutant of HPV-18E6 was constructed. As experiments with either neutral (Val) or acidic (Glu) substitutions of the phosphoacceptor Thr 156 were negative for Dlg binding (Gardiol et al., 1999) ) was destroyed by substituting Arg 153 with Leu. As predicted, this mutation destroyed the PKA phosphorylation site ( Figure 1D ) but not the PDZ binding domain of HPV-18E6 in vitro (data not shown). This HPV-18E6 derivative (18E6-Leu 153 ) catalyses degradation of HA-Dlg in an E6 dependent, constitutive manner. This degradation was independent of the cellular PKA levels ( Figure 5A, lanes e,f,g ). The speci®city of this activity of E6 was further analysed by performing parallel p53 degradation assays in the presence of high and low PKA activity. As can be seen from the results shown in Figure 5B it is clear that the ability of E6 to target p53 for degradation is unaected by the PKA activity. Taken together, these experiments show that HPV-18E6 targeted degradation of Dlg is directly regulated by a PKA phosphorylation at the Thr 156 of HPV-18E6 in vivo. (7) or high (+) PKA levels in HEK 293 cells. Cells were transfected with 2 mg Dlg expression plasmid plus 1.5 mg of the 18E6 expression plasmid as indicated, together with 6 mg PKAcat. expression plasmid in tracks c and f. In tracks d and g cells were treated with 1 mM IBMX, 20 mM Forskolin 1 hr prior to harvesting. Remaining Dlg levels were ascertained by Western blot analysis with an anti HA antibody. The lower panel shows the western blot analysis of b-galactosidase (b-Gal) which served as an internal transfection and loading control marker, B, E6 mediated degradation of p53 is not regulated by PKA. p53 in vivo degradation assays were performed under low (7) or high (+) PKA conditions in HEK 293 cells. Cells were transfected with a six histidine tag-containing p53 expression construct in order to distinguish it from endogenous p53, and p53 protein was analysed in a Western blot using p53 speci®c antibodies (upper panel) (a) 2 mg pCDNA3-His 6 , (b) 2 mg pCDNA3-His 6 -p53, (c) 2 mg pCDNA3-His 6 -p53, 1.5 mg pCDNA3-18E6-WT, (d) 2 mg pCDNA3-His 6 -p53, 1.5 mg pCDNA3-18E6-WT, 6 mg pPKA cat., (e) 2 mg pCDNA3-His 6 -p53, 1.5 mg pCDNA3-18E6-WT treated 1 h prior to extraction with 1 mM IBMX and 20 mM Forskolin. All transfections were done as outlined in A. Internal transfection, and loading-control marker was a six histidine tagcontaining b-galactosidase expression construct (b-Gal) (lower panel), detection was as in A (C) PKA activities were obtained from triplicate assays at two dierent linear extract concentrations; standard deviations are shown. Assays were done using a peptide containing a PKA consensus site fused to the C-terminus of GST (GST-PKA In contrast to hDlg, the E6 mediated degradation of p53 was unaected by the levels of PKA activity and, so far, we have no evidence of any cell dependent regulation of the E6/E6-AP mediated turnover of p53 (KuÈ hne C, Gardiol D and Banks L, unpublished results). We can conclude however, that E6 mediated degradation of dierent cellular targets is subject to dierent forms of regulation and it will also be intriguing to evaluate the role for the recently described PKN phosphorylation of E6 (Gao et al., 2000) on its ability to target dierent cellular proteins.
The molecular basis for the dierential regulation of E6 mediated degradation of hDlg is provided by the results from the mutational analysis of E6 and the molecular modelling. These studies show that there is functional interplay between E6/Dlg binding and PKA phosphorylation due to the overlap of the PKA phosphorylation site in E6 with its hDlg binding motif. A striking feature of this PKA/Dlg recognition motif is its strict conservation amongst the high-risk HPV E6 proteins. A multiple alignment of the HPV E6 protein sequences reveals a strictly conserved PKA phosphorylation site consensus motif with a Thr, corresponding to Thr 156 in HPV-18 E6, being the putative phosphoacceptor site in all the high-risk HPV E6 proteins ( Figure 6 ). Signi®cantly this PKA/Dlg recognition module is absent in the low-risk HPV E6 proteins, suggesting that PKA regulated degradation of hDlg is an essential function of the high-risk HPV E6 proteins.
It is likely that the strict conservation of an invariable E6 C-terminus for all the high-risk mucosal virus types re¯ects an important role in HPV tumour progression. At present it is not clear what role the extreme C terminal PDZ binding domain of E6 plays in transformation in vitro. One report would suggest that an intact PDZ binding domain was essential for the ability of E6 to transform rodent cells (Kiyono et al., 1997) , whereas other studies would suggest that it was not required for keratinocyte and mammary epithelial cell immortalization (Kiyono et al., 1998; Liu et al., 1999) . However, this latter point may well be a re¯ection of the arti®cially high levels of E6 used in some assays, since in the context of an intact HPV 18 genome, mutants of E6 defective in PDZ binding are defective in keratinocyte immortalization (C Meyers, personal communication). However, based on studies which show that E6 induced tumours in transgenic animals exhibit high levels of malignant potential (Pan and Griep, 1994, 1995; Song et al., 1999) , together with the ascribed functions of Dlg, we favour the hypothesis that E6 induced degradation of hDlg has a role in the late stage progression of HPV induced malignant tumours. The importance of a regulated, conditional function of the E6 C-terminus most likely re¯ects the requirement for a number of ordered dierent oncogenic functions to bring about progression to late malignant stages of cervical tumours. In the case of high-risk virus infections, the calcium and serum induced terminal dierentiation (which leads to keratinization and subsequent cell death) is inhibited, and the viral E6 protein has been shown to interfere with these steps (Sherman et al., 1997; Sherman and Schlegel, 1996) . It is at this stage that the loss of Dlg function could be crucial for tumour formation. In earlier phases however, a functional Dlg signaling might be essential for basal cell dierentiation and to regulate cell to cell contact at tight junctions. In the later stages of tumour progression, constitutive low levels of cAMP, resulting either from low inducer concentrations (i.e. low adrenaline), mutations in the cAMP/PKA pathway, or mutations in pathways that show cross-talk with the cAMP responses, might lead to a change in the E6/PKA responsiveness. This should lead ultimately to low levels or complete constitutive loss of the tumour suppressor Dlg. Mutations that disrupt the normal patterns of PKA activation are frequently found in malignancy (Boynton and White®eld, 1983; Cho-Chung, 1990 ). In fact, our preliminary results suggest frequent perturbations at dierent levels of the PKA signalling pathway in many of the HPV positive cervical carcinoma derived cell-lines (C KuÈ hne unpublished results). In this context, it is tempting to speculate that a change in the responsiveness of the PKA pathway in keratinocytes could represent an Figure 6 Conservation of a PKA phosphorylation site overlapping with the Dlg substrate consensus motif at the C-termini of high risk HPV E6 proteins. Representative alignment of the Cterminal ends of the E6 proteins from the most frequently found HPV types associated with cervical carcinoma (HPV 16, 18, 31, 33, 35, 45 ) and compared with low risk types (HPV 1, 2, 3, 6, 8, 11) . PKA consensus motif in bold, Dlg binding motif underlined. Alignments were done relative to the last cysteine residue from the predicted second zinc-®nger essential, cellular risk factor for the manifestation of malignancy in cervical cancer.
Future studies aim to analyse the consequences of dierential degradation of hDlg during progressive stages of HPV induced malignancy. This should allow us to determine whether activation of the cAMP pathway is a valid therapeutic option during cervical carcinogenesis.
Materials and methods
Cell extraction, kinase assays and K m determination Serum starved Swiss 3T3 cells were released for 10 min into G1 with EGF/Insulin and extracts were prepared and used for kinase assays as described previously (Edelmann et al., 1996) . For the kinase assay shown in Figure 1A , extracts were frozen at 7708C and quickly thawed in a 378C water bath (this explains why PKA can be detected from early G1 cells as freezing and thawing was shown to release PKi from the catalytic PKA subunit). For measurement of the PKA response to the activators in HeLa, HaCaT and HEK293 cells, a GST protein containing a PKA phosphorylation site (GST-PKA) (Hateboer et al., 1993) was used as a substrate. His tagged S6 kinase was expressed in baculovirus and puri®ed from Sf9 cells on Ni
2+
-NTA-agarose, PKB (Akt1) and p90 rsk were obtained from immunoprecipitations with speci®c antibodies; the activity of PKB was ascertained on MBP and p70S6K, and p90rsk on 40S ribosomal subunits as substrates as described (Edelmann et al., 1996) . Protein concentrations in the cell extracts were determined by a Lowry method (Edelmann et al., 1996) . The concentrations of GST and His-tag proteins used were assessed from Coomassie stained SDS ± PAGE gels by comparison with BSA standard-dilutions.
For the determination of the K m values for phosphorylation, radiolabeled E6 was determined from protein gel assays by phosphoimager analysis of GST-18E6 relative to the total amount of input ATP. The K m was then determined graphically using Lineweaver ± Burk diagrams from the data obtained. For these calculations, we eliminated the lowest and highest values in the data series from each individual concentration. For the determination of the K m for E6 peptides, aliquots of the kinase assays were spotted onto P81 Phosphocellulose Ion Exchange Chromatography paper (Whatman) and analysed as described above.
Recombinant proteins, GST binding assay and peptides
GST, GST-11E6, GST-16E6, GST-18E6, GST-18E6Val156 and GST-Dlg proteins were prepared from bacterial lysozyme lysates after centrifugation at 100 000 g and glutathionesepharose chromatography (KuÈ hne and Banks, 1998). His-18E6 was prepared under denaturing conditions in the presence of 6M guanidinium HCl and renatured as described previously (KuÈ hne and Banks, 1998) . All the peptides used in this study were synthesized with Fmoc chemistry on an automatic synthesiser. The Phospho-Threonine containing peptide was synthesized by using Thr (PO3) Fmoc building blocks (Bachem). All peptides were puri®ed by reverse phase HPLC and identity con®rmed by mass-spectroscopy. GST binding assays were done as described previously (KuÈ hne and Banks, 1998) with minor modi®cations as follows: binding buer was 20 mM Tris pH 8.0, 5 mM EDTA, 100 mM NaCl, 20 mM TPCK, 20 mM TLCK, 0.2 mM NaF and 30 mM 4-nitrophenyl phosphate (pNPP). All the binding reactions were performed for 30 min at room temperature, reaction volume was 100 ml and washing was done four times in binding buer containing 0.2% NP40. Quantitative phosphorylation of the His-18E6 substrate was done with puri®ed PKA (Sigma) in the presence of 100 mM ATP for 3 h at 308C. After 2 h additional enzyme was added. Input phosphate was estimated by the use of [ 32 P]gATP and calculated relative to an HisE6 protein-input estimated by SDS ± PAGE.
Plasmids pGST-Dlg, pCMV-HA-DLG, pCMV-HA18E6 were as described previously (Lee et al., 1997) , the PKA expression vector was generously given by SG McKnight (Uhler and McKnight, 1987) , pcDNA3-18E6, pCDNA3-18E6Leu153, were cloned with PCR as a BgIII/EcoRI fragment into the BamHI/EcoRI of pCDNA3 (Invitrogen). pGST-18E6 and pGST-18E6Val156 are BglII/EcoRI clones into the pGEX2T vector, pGST-11E6 and pGST-16E6 and pETHis18E6 were as described previously (KuÈ hne and Banks, 1998). pHis 6 -p53 was cloned as a BamHI/EcoRI PCR fragment into the vector pcDNA3-1HisA (Invitrogen). The identity of the clones was veri®ed by didioxy-sequencing, pCDNA-HisLacZ was from Invitrogen.
Cell culture, transfections and in vivo labelling
Cells were maintained in DMEM supplemented with 10% foetal calf serum. HEK 293 cells were transiently transfected at a density of 0.8610 6 /10 cm dish, using the calcium phosphate precipitation method. PKA activators forskolin (20 mM) (Sigma) and 3-Isobutyl-1-Methylxanthine (1 mM) (IBMX) (Sigma) if used, were added 1 h prior to harvesting the cells. For in vivo labelling with 32 P-orthophosphate, transfected HEK 293 cells were ®rst washed in phosphate free medium containing 10% dialysed foetal calf serum, incubated for 1 h without phosphate and then for 4 h in the presence of 0.5 mCi/ml [ 32 P]orthophosphate (Amersham). Protein extracts from these labelling were then proceeded for immunoprecipitations.
Immunoprecipitations and Western blots
Cell lysis from in vivo radiolabelled cells was done in buer A (50 mM Tris pH 7.5, 500 mM NaCl, 0.2 mM EDTA, 0.2 mM EGTA, 0.5% NP40, 20 mM TPCK, 20 mM TLCK, 50 mM LLnL, 5 mM N-ethyl-maleimide (NEM, Sigma), 0.2 mM NaF and 30 mM 4-nitrophenyl phosphate in the presence of 0.1% SDS, 0.5% sodium deoxycolate and 10 mM protein kinase A inhibitor peptide (PKi) (Sigma). Following lysis, extracts were sonicated and cleared by centrifugation. For immunoprecipitations these samples were diluted 1 : 5 with buer B (buer A but containing no NP40, NaCl, SDS or DOC) and precleared in a mixture of protein A and protein G-sepharose prior to incubation with a mixture of the anti HA monoclonal antibodies 16B12 (2 mg/ml) (Babco) and 12CA5 (Roche-Diagnostics) (2 mg/ml) at 48C (preincubated in 10 mg/ml BSA) (KuÈ hne and . Precipitation was done with a mixture of protein A and protein G sepharose and washed three times in a ®vefold diluted buer A in buer B. For Western blots, cells were collected 24 h after transfection and washed with PBS and pellets were boiled in loading buer containing 2% SDS and 0.1 M DTT. The His-tagged p53 expressed protein was prepared with 6M Guanidinium HCl containing buers and successive Ni 2+ -NTA-agarose anity chromatography as described (KuÈ hne and Banks, 1998) . Western blots were developed using peroxidase-conjugated secondary antibodies and the Enhanced Chemoluminescence substrates (Amersham).
Antibodies and confocal microscopy
For confocal analysis of the Dlg protein, HaCaT or HeLa cells were grown on adhesion slides in the presence of 2.5 mM CaCl 2 and PKA activators were added overnight as indicated. Cells were ®xed in 3% paraformaldehyde in PBS, incubated for 5 min in 0.1% Triton/PBS, stained with a-hDlg antibody (1 mg/ml) and detected with a FITC-conjugated secondary antibody (Sigma). In addition cells were also stained for DNA with propidium-iodide following RNAse A digestion. Images were analysed with a Zeiss Axiovert 100M microscope attached to a LSM 510 confocal unit. The antibodies used for Western blot and immuno¯uorescence analyses were the aHA antibodies 16B12 (Babco) and 12CA5 (Roche-Diagnostics); mouse ap53 (mAB1801) (Banks et al., 1986) , anity puri®ed rabbit aHPV-18E6 (KuÈ hne and ; and mouse ahDlg (2D11), goat aAKT1 (C-20), goat ap90rsk (C-21) (all Santa Cruz, Biotech.).
Molecular modelling
The structural modelling predictions were done with the Insight II (Biosym Technologies) package on a Silicon Graphics work station using the PDB ®le coordinates from the Brookhaven Database. The molecular-models for the HPV 18E6 C-terminus in its phosphorylated and non phosphorylated state were built based on the following assumptions. The PDZ domains of pdz95 and pdz97 Dlg have been determined and are superimposable (Cabral et al., 1996; Doyle et al., 1996) . Crystal structure analysis of the Dlg paralogue psd95 PDZ domain in complex with its binding-peptide has been reported (Doyle et al., 1996) . Substrate recognising and interacting amino acids in the PDZ domains are conserved between psd95 and hDlg (Doyle et al., 1996) . Peptide bound and unbound PDZ domains as determined for psd95 do not dier in structure (Doyle et al., 1996) . Finally, we rebuilt the psd95 substrate peptide using the same methodology as for the hDlg substrate 18E6 and obtained a minimal energy structure that was superimposable with the crystal structure (40 residues 0.3 A Ê ) (data not shown).
